Articles tagged with Platelets
Researchers at UNC have identified CIB1 as a 'gatekeeper' protein that inhibits platelet-to-platelet interactions in the blood. By binding to GPIIb/IIIa, CIB1 prevents platelet activation and clot formation.
Researchers have discovered that polyphosphate accelerates blood clotting and delays its breakdown, leading to longer-lasting clots. The Center for Hemostasis Research at the University of Illinois will continue to study this discovery to develop effective treatments for uncontrollable bleeding.
Researchers found that dark chocolate improved arterial flow and reduced platelet activity, benefiting vascular health in smokers. A daily treat of 40g dark chocolate improved smoothness of arterial flow for eight hours.
A long-term study showed that AMG 531 increased platelet counts in patients with immune thrombocytopenic purpura (ITP), with 47% of patients experiencing a durable response. The treatment was generally well-tolerated, but some serious adverse events were reported.
Researchers found that certain carbon nanoparticles activate human platelets and stimulate blood clotting, leading to increased risk of cardiovascular disease. The study also revealed that some nanoparticles mimic molecular bridges involved in platelet interactions.
Prestoraged pooled platelets have been shown to have an equivalent clinical response and quality to platelets pooled at the time of transfusion, increasing platelet availability and reducing hospital costs. The Pall eBDS System has demonstrated high sensitivity in detecting bacteria in pooled platelets.
Researchers at Max Planck Institute have found that the surface of lime platelets in mother-of-pearl is disordered and wavy, ruling out ordered layers on the organic matrix. This discovery challenges previous understanding of nacre's composition and mechanism, offering new insights into building materials.
University of Utah researchers found that splicing, a process that codes for inflammatory protein Interleukin 1â (IL-1â), takes place in the cytoplasm of circulating platelets. This finding has potential implications for understanding gene expression and disease mechanisms.
Research shows that cocoa's flavinoids can inhibit platelet function, potentially preventing coronary heart disease. In contrast, people with non-O blood types are at increased risk of deep vein thrombosis (DVT), particularly those carrying the Factor V Leiden variant protein.
A new mouse model mimics the effects of low-dose aspirin therapy, reducing platelet aggregation and inhibiting thrombosis. The study suggests that low-dose aspirin treatment may prevent preeclampsia without compromising reproductive function.
A small study found that St. John's wort amplifies the effect of blood thinner Plavix, potentially increasing the risk of bleeding among those who take both. The researchers plan to conduct further studies to confirm the finding and explore its implications for new drug development.
The McMaster researchers developed a detailed bleeding history questionnaire to discriminate between patients with QPD and those without. The tool helps identify higher likelihoods of bleeding that leads to lifestyle changes, bruises or bleeding in joints, providing valuable clues for doctors diagnosing the condition.
Research demonstrates that platelet aggregation and the release of LPA support bone metastases in breast cancer. Inhibiting platelet activity with Integrilin or targeting LPA signaling may slow tumor growth and reduce metastasis.
Individuals with obesity produce more toxic oxygen molecules that lead to changes in fat-derived hormones and contribute to the development of metabolic syndrome. Treatment with antioxidants reduces ROS production and improves diabetes symptoms.
A study found that Concord grape juice increased high-density lipoprotein (HDL) levels and decreased inflammatory markers, including soluble CD40 ligand, in patients with coronary artery disease. The positive effects were attributed to the polyphenolic compounds in the grape juice.
Research suggests that binge drinking has a detrimental effect on platelet adhesion and aggregation, leading to increased risk of cardiovascular mortality. In contrast, moderate red wine consumption may have beneficial effects on cardiovascular disease due to its high polyphenol count.
Researchers have discovered that nonalcoholic beer can impart cardiovascular benefits without the negative effects of alcohol. The study found that nonalcoholic beer reduced platelet activation and blood coagulation just as well as alcoholic beverages, which may help prevent conditions such as coronary heart disease and atherosclerosis.
Researchers found that platelets can promote diabetic complications and contribute to inflammation in heart disease. They discovered a common Type II diabetes drug can dampen platelet inflammatory activity, potentially leading to new treatments for vascular diseases.
Researchers developed a neural network software that predicts the best dose strategy for individual patients based on 17 characteristics. The new approach showed potential for dose prescription improvement, reducing risk of adverse side effects.
Researchers found that the hormone estradiol plays a crucial role in proplatelet formation, enabling the creation of new blood platelets. This discovery may lead to alternative treatments for conditions such as anemia and thrombocytopenia.
Researchers found that platelets in heart disease patients clot more easily despite taking aspirin, increasing the risk of heart attack. Further studies will investigate additional anti-clotting agents and genetic factors affecting platelet function.
Researchers found that an anti-platelet drug, ML464, blocked bone metastases and reduced new tumor development in mice. The study provides a promising start to exploring the use of anti-platelet drugs as potential therapies for breast and prostate cancer.
Researchers have found a way to extend the lives of chilled platelets after transfusion, potentially increasing the platelet supply and making it easier to transport. This breakthrough could help more patients receive life-saving platelet transfusions.
Researchers found that 8 out of 20 commonly used NSAIDs can selectively lower Abeta42 levels in mice, with flurbiprofen showing the most promise. Additionally, studies revealed increased T cell reactivity to Abeta protein in older humans and patients with Alzheimer's disease, which could inform the design of future vaccines.
Scientists identify key amino acid sequence responsible for activating GPIIb-IIIa molecule, a crucial component of platelet function. This discovery provides new insights into how integrins on cells throughout the body may function.
A new study reveals that Viagra encourages platelets to aggregate, potentially leading to thrombosis and life-threatening conditions like heart attacks and strokes. The researchers found that the drug's active ingredient raises levels of cGMP, which initially causes platelets to clump but later reverses to prevent excessive buildup.
Researchers found that tirofiban and abciximab were equally effective in preventing longer-term events such as death, heart attacks, and repeat surgery after coronary-artery angioplasty. The study's conclusion was that while abciximab is more expensive, it provides little long-term advantage compared to tirofiban.
Researchers discover that a platelet molecule called phosphatidylserine plays a key role in activating the final step of blood coagulation. The finding could lead to new treatments for clotting disorders, such as heart attacks and strokes.
Researchers at Washington University School of Medicine have found that a defective form of vWF causes chemical bonds to persist longer than they should, leading to a bleeding disorder. The defect in the vWF protein changes the kinetics of the chemical bonds between the protein and platelets, resulting in the disease.
Researchers at Brown University have discovered that the Arp2/3 protein complex plays a critical role in regulating the first step of human blood clotting. The complex drives platelets to change shape, forming long arms that grab onto other cells and fibrin, ultimately leading to clot formation.
Penn researchers used laser tweezers to study the strength of ligand-receptor binding in platelets, refining the paradigm of how blood clots form. They found that changes in integrin's ability to bind to fibrinogen are regulated by the cell as an all-or-none phenomenon with only one functional state compatible with binding.
The balancing act between COX-1 and COX-2 enzymes plays a crucial role in protecting the heart from cardiovascular disease. The study found that PGI2 production is stimulated as a response to platelet interactions with the vessel wall, limiting the harmful effects of thromboxane.
A study has shown that chilling causes changes in the platelets' outer membrane, leading to the formation of lipid rafts. This process is a general first step in platelet activation, which can lead to blood clots and heart attacks.
A team of researchers at UC Davis has developed a method to freeze-dry platelets, which can be stored for at least a year without refrigeration. The innovation uses trehalose, a natural protectant found in certain animals and plants, to preserve the structure of proteins and other large molecules.
A new bacteria test has shown promise in detecting contaminated platelets before they are used for transfusion, reducing the risk of severe illness and death. The Pall BDS system measures oxygen levels in a sample obtained from a platelet unit, indicating bacterial contamination and allowing for safe disposal.
New York University researchers found an antibody that destroys platelets, which are essential for the blood to clot. The discovery may lead to new treatments for thrombocytopenia, a condition associated with HIV infection and other vascular diseases.
Febrile reactions occur in around a third of platelet transfusions. Researchers propose that CD40 ligand release from platelets triggers the production of proinflammatory prostaglandin E2, leading to fever. Keeping CD40 ligand levels low before transfusion might reduce adverse events.
A study found that consuming high-procyanidin chocolate increased plasma concentrations of a procyanidin metabolite and reduced serum leukotriene, promoting blood platelet aggregation. This compound may provide cardioprotective effects by inhibiting platelet aggregation.
A University of Maryland study found that high cholesterol hinders the effectiveness of aspirin in reducing platelet aggregation and preventing heart attacks. The study showed that 60% of patients with high cholesterol levels above 220mg/dL remained at increased risk despite taking daily aspirin doses.
A study found that moderate alcohol consumption can inhibit internal platelet aggregation, reducing the risk of heart attacks and coronary artery disease. However, the study's lead author emphasized that individual drinking habits should not be directly linked to the findings.
The trial found that eptifibatide significantly reduced deaths and heart attacks by 40% within the first 48 hours of use. This represents a substantial improvement over the current standard treatment, abciximab, which costs $1,500 compared to $400 for eptifibatide.
Researchers found that cold temperature needed to preserve livers for transplant also kills sinusoidal endothelial cells, highly specialized liver cells. This discovery suggests a possible drug target and could lead to changes in liver transplant protocols.
Researchers at Jefferson Medical College have uncovered a potential switch that helps control the manufacture of red blood cells and blood-clotting platelets. Activating 'death receptors' on immature red blood cells triggers caspases, which can halt excessive production by blocking cell growth and differentiation.
Researchers at UNC-CH have developed a gene therapy method that targets specific types of cells, avoiding the less effective 'shotgun' approach. The technique successfully corrects genetic defects in primitive stem cells, which can be used to treat inherited blood disorders like hemophilia and non-inherited illnesses such as cancer.
A study found that patients taking selective serotonin reuptake inhibitors (SSRIs) had a reduction in sticky platelets, which can contribute to heart problems. The researchers suggest that improved mood is the key factor behind this effect.
Researchers at the University of Delaware are studying a protein called CIB, which helps pair sticky fibrinogen with hook-like receptors on blood platelets. The discovery may lead to new remedies for blocking platelet aggregation and shedding light on cell migration.
A study by Jane E. Freedman found that purple grape juice inhibits platelet aggregation, reducing blood clotting risk and improving cardiovascular health. The flavonoid quercetin was also shown to have antioxidant properties, preventing the inactivation of nitric oxide.
Researchers at UCSF have discovered a new molecular mechanism that activates platelets, leading to clot formation. The discovery of protease-activated receptor 4 (PAR4) may lead to new approaches for developing drugs to prevent heart attacks and strokes.
A team of researchers led by Dr. Joel Bennett has successfully developed a new technique to study the IIb/IIIa receptor, a key player in platelet aggregation. This breakthrough could pave the way for the creation of more potent anti-clotting drugs.
Researchers at Johns Hopkins Medicine have identified a unique molecular defect responsible for polycythemia vera, a blood disorder that can be difficult to diagnose. The finding may lead to the development of a definitive test for the condition, which could potentially increase patient lifespan.
Researchers have found a genetic component to blood clotting abnormalities that increase the tendency of forming dangerous clots on the inside lining of blood vessels. The studies suggest that genetic variations in certain genes may contribute to increased risk of heart disease and stroke.
A thin polymer coating on coronary arteries may prevent platelet formation and reduce the risk of acute thrombosis following angioplasty. The study found significant inhibition of platelet deposition for at least one hour, supporting a novel treatment approach.
Researchers developed a synthetic human hormone that triples platelets received from each donor, improving recovery of platelets in patients undergoing chemotherapy. An increased supply would give physicians more options for treating chemotherapy patients and make transfusions more affordable.
Researchers found that polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor (MGDF) significantly increased platelet counts in patients with advanced non-small-cell lung cancer after chemotherapy. Platelet counts returned to normal within 14 days, faster than in placebo recipients.